XML 46 R29.htm IDEA: XBRL DOCUMENT

INTANGIBLE ASSETS (Tables)

12 Months Ended

Dec. 31, 2015

Goodwill and Intangible Assets Disclosure [Abstract]

Schedule of intangible assets

The following table sets forth the gross carrying amount, accumulated amortization and net carrying amount of our intangible assets as of December 31, 2015 and 2014:

		December 31, 2015
		Gross Carrying Amount				Accumulated Amortization				Net Amount				Weighted- Average Remaining Amortization Period (yrs.)
Amortizable intangible assets:
OPERA^® software patent		$	31,951			$	(4,493	)		$	27,458				13.75
Development costs of corporate website			91,743				(91,743	)			—				n/a
Approved hormone therapy drug candidate patents			705,752				(49,845	)			655,907				17
Hormone therapy drug candidate patents (in process)			774,165				—				774,165				n/a
Non-amortizable intangible assets:
Multiple trademarks for vitamins/supplements			157,721				—				157,721				indefinite
Total		$	1,761,332			$	(146,081	)		$	1,615,251

		December 31, 2014
		Gross Carrying Amount				Accumulated Amortization				Net Amount				Weighted- Average Remaining Amortization Period (yrs.)
Amortizable intangible assets:
OPERA^® software patent		$	31,951			$	(2,496	)		$	29,455				14.75
Development costs of corporate website			91,743				(91,743	)			—				n/a
Approved hormone therapy drug candidate patents			439,184				(19,401	)			419,783				18
Hormone therapy drug candidate patents (in process)			675,982				—				675,982				n/a
Non-amortizable intangible assets:
Multiple trademarks for vitamins/supplements			103,368				—				103,368				indefinite
Total		$	1,342,228			$	(113,640	)		$	1,228,588

Schedule of estimated amortization expense

Estimated amortization expense for the next five years is as follows:

Year Ending December 31,				Estimated Amortization
	2016			$	40,580
	2017			$	40,580
	2018			$	40,580
	2019			$	40,580
	2020			$	40,580